Status
Ongoing
Marketed without an Approved NDA/ANDA: FDA analysis found the products to be tainted with undeclared Furosemide, Dexamethasone and Chlorpheniramine
Status
Ongoing
Classification
Class I
Report Date
January 15, 2025
Termination Date
—